Oric Pharmaceuticals Publishes Promising Data on Brain-Penetrant EGFR Inhibitor Enozertinib for NSCLC
Reuters
Nov 07, 2025
Oric Pharmaceuticals Publishes Promising Data on Brain-Penetrant EGFR Inhibitor Enozertinib for NSCLC
Oric Pharmaceuticals Inc. has announced the publication of a peer-reviewed research paper in Cancer Research detailing the discovery and development of enozertinib, a highly selective, brain-penetrant EGFR inhibitor. Enozertinib, also known as ORIC-114, is designed to target EGFR exon 20 and atypical mutations in non-small cell lung cancer (NSCLC). According to Oric Pharmaceuticals, preclinical data demonstrate enozertinib's potency, selectivity, brain penetration, and anti-tumor activity, including in intracranial lung cancer models. The company has also highlighted a patient case in which enozertinib achieved a sustained complete response in both systemic and brain metastases. Oric Pharmaceuticals plans to present additional clinical data on enozertinib at ESMO Asia 2025 in December and further data in mid-2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568990-en) on November 06, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.